MoFo Life Sciences

March 03, 2021 - AI + Robotics, United States, FDA, Regulatory
FDA’S PLAN FOR AI/ML-BASED SOFTWARE AS MEDICAL DEVICES: PROGRESS AND CONCERNS
By: Jean Nguyen Ph.D.
U.S. Food and Drug Administration (FDA) has acknowledged the prevalence of Artificial Intelligence/Machine Learning (AI/ML)-Based Software as Medical Devices (SaMDs) and has been taking steps towards advancing its regulatory oversight. The FDA recently published an AI/ML SaMD action plan, developed in direct response to
... ›
March 02, 2021 - United States, European Union, Intellectual Property
Key EU Intellectual Property and Trade Secrets
By: Wolfgang Schönig and Mark L. Whitaker
Session 11 of the GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start Ups was led by Life Sciences Transactions + Licensing partner Wolfgang Schoenig focusing on key EU Intellectual Property. Wolfgang discussed Intellectual Property Rights,
... ›
February 04, 2021 - United States, Litigation, Regulatory
EHR Vendor Settles Kickback Allegations to the Tune of $18.25 Million
On January 28, 2021, the United States’ Department of Justice (DOJ) announced an $18.25 million settlement with athenahealth Inc. (“Athena”) to resolve allegations that Athena violated the False Claims Act by paying impermissible kickbacks related to its electronic health records (EHR) product. At the
... ›
January 19, 2021 - Licensing + Commercial, United States, European Union
Top 10 Considerations When Drafting and Negotiating SRAs, with U.S. and EU Perspectives
By: Wolfgang Schönig, Matt Karlyn and Robert Grohmann
Sponsored Research Agreements (SRA) are used by companies to contract a research organization, such as a university, to conduct research and development activities in exchange for fees and the university’s rights to use the results for general research purposes. Care should be taken to
... ›
January 05, 2021 - United States, Litigation, Intellectual Property
Considerations for ANDA and BPCIA Litigation
By: Matthew A. Chivvis and Michael Ward Ph.D.
Matthew Chivvis , life sciences IP litigation partner in Morrison & Foerster’s San Francisco office led session 5 of our course on Legal Topics for Scientists, Entrepreneurs, and Start Ups. Matthew discussed the Hatch-Waxman and Biologics Price Competition and Innovation Act for generics and
... ›
December 14, 2020 - United States, FDA, COVID-19, Pharma
FDA Authorizes First COVID-19 Vaccine
Late last week, the U.S. Food and Drug Administration issued the first Emergency Use Authorization (EUA) for a COVID-19 vaccine in the United States. The vaccine is manufactured by Pfizer Inc. and BioNTech SE. It consists of two doses taken three weeks apart, and
... ›
November 20, 2020 - United States, FDA, COVID-19
FDA Authorizes First Full At-Home Test for the Detection of SARS-CoV-2
On November 17, 2020, FDA issued the long-awaited first emergency use authorization (EUA) for a COVID-19 diagnostic test for self-testing at home. The test, the Lucira COVID-19 All‑In‑One Test Kit, can be conducted completely at home by anyone age 14 or over, by collecting
... ›
November 17, 2020 - United States, FDA, Healthcare
Recent Digital Health-Related FDA Announcements
By: Jean Nguyen Ph.D.
The U.S. Food and Drug Administration (FDA) is showing its dedication to the advancement of digital health technology with two recent announcements: a new Digital Health Center of Excellence and an update on its Software Precertification Program. Manufacturers developing mobile medical devices, software as
... ›
November 17, 2020 - United States, Corporate + Venture Capital, United Kingdom, Startup, Intellectual Property
GSAS Harvard Biotech Club and Morrison & Foerster’s New Course
By: Andrew Boyd, Alfredo B. D. Silva, Anita Choi and Michael Ward Ph.D.
MoFo & GSAS Harvard Biotech Club’s new course, “ Legal Topics for Scientists, Entrepreneurs, and Start Ups ,” started on November 11, with more than 100 life sciences graduate students, post-docs, and industry professionals. The Harvard Biotech Club is a student organization that seeks to
... ›
October 17, 2020 - Licensing + Commercial, United States, Corporate + Venture Capital
Life Sciences Startup: Top Things to Keep in Mind About Formation and License Agreements
By: Steve Rowles, Matt Karlyn and Michael Ward Ph.D.
During our fifth Patent Law Course session offered by Morrison & Foerster and GSAS Harvard Biotech Club , Steve Rowles, firmwide co-chair of the Emerging Companies & Venture Capital Group , chair of MoFo’s San Diego Corporate Group, and managing partner of the San
... ›

Topic Archives: United States

FDA’S PLAN FOR AI/ML-BASED SOFTWARE AS MEDICAL DEVICES: PROGRESS AND CONCERNS

By: Jean Nguyen Ph.D.

Key EU Intellectual Property and Trade Secrets

By: Wolfgang Schönig and Mark L. Whitaker

EHR Vendor Settles Kickback Allegations to the Tune of $18.25 Million

Top 10 Considerations When Drafting and Negotiating SRAs, with U.S. and EU Perspectives

By: Wolfgang Schönig, Matt Karlyn and Robert Grohmann

Considerations for ANDA and BPCIA Litigation

By: Matthew A. Chivvis and Michael Ward Ph.D.

FDA Authorizes First COVID-19 Vaccine

FDA Authorizes First Full At-Home Test for the Detection of SARS-CoV-2

Recent Digital Health-Related FDA Announcements

By: Jean Nguyen Ph.D.

GSAS Harvard Biotech Club and Morrison & Foerster’s New Course

By: Andrew Boyd, Alfredo B. D. Silva, Anita Choi and Michael Ward Ph.D.

Life Sciences Startup: Top Things to Keep in Mind About Formation and License Agreements

By: Steve Rowles, Matt Karlyn and Michael Ward Ph.D.